Subscribe
The history of the Soviet German Democratic Republic reveals the benefits and shortfalls of state-owned drugmakers
As activists add to the pressure on the GlaxoSmithKline board ahead of a proposed demerger, Robin Hardy asks if it will create value for shareholders
Newly-listed consolidation platform has huge promise, but won鈥檛 turn a profit for years
As the UK emerges from lockdown, share prices are beginning to recover. But the burden of a big debt pile means that some companies may have rerated too strongly.
An internal investigation into Nestle鈥檚 products has raised some thorny questions about its future
Inflation will rise in the next few months. But 鈥� with some potential caveats 鈥� it is unlikely to stay high
Without government-provided stimulus, can the housebuilders keep delivering for their shareholders?
The ultimate guide to the core of the markets
Knowing the drivers of a share's total returns can help you make better investment decisions
Get to know investment trusts with the help of our handy guide
